Research programme: inflammation therapeutics - VBL TherapeuticsAlternative Names: VB-202; VB-302
Latest Information Update: 12 Jan 2017
At a glance
- Originator Vascular Biogenics
- Developer VBL Therapeutics
- Class Phospholipids; Small molecules
- Mechanism of Action Cytokine inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Atherosclerosis; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 11 Jan 2017 Research programme: inflammation therapeutics - VBL Therapeutics is available for licensing as of 09 Jan 2017.
- 06 Oct 2014 Preclinical development is ongoing in Israel
- 02 Dec 2010 Preclinical development is ongoing in Israel